‘Molecular switch’ could reverse the effects of alopecia
A Phase IIa clinical trial has begun evaluating the safety and efficacy of Pelage Pharmaceuticals’ PP405, a novel topical small molecule, for the treatment of androgenetic alopecia (pattern baldness).
The company is enrolling 60 women and men for the clinical study. PP405 is designed to reactivate dormant hair follicle stem cells to stimulate hair growth.
Pelage also raised a $14 million Series A-1, led by GV, following an initial $16.75 million Series A financing announced in February 2024.
The Series A-1 follows positive Phase I data, which demonstrated proof of mechanism and target engagement in patients with androgenetic alopecia, supporting a Phase II study.
“The advancement of our lead programme, PP405, into Phase IIa is a pivotal moment in our journey to deliver a non-invasive, innovative treatment for androgenetic alopecia across all genders, skin types, and hair types,” said Qing Yu Christina Weng, Chief Medical Officer, Pelage Pharmaceuticals. “We are excited to include women and men of all skin tones and hair textures, which has not always been the case in hair loss studies.”
Reactivating hair growth
PP405 addresses the metabolic processes that regulate activation of hair follicle stem cells.
In androgenetic alopecia, the normal growth cycle of hair is disrupted due to a combination of genetics, age, hormones, and environmental factors, but the follicles and stem cells remain intact.
PP405 is based on the discovery of a molecular switch that specifically targets hair follicle stem cells to reactivate dormant processes and restore the growth cycle of hair.
The Phase IIa trial is a randomised, placebo-controlled study of PP405 in women and men with androgenetic alopecia.
Pelage has also announced the formation of its Clinical Advisory Board (CAB), which will include Mathew Avram, Associate Professor of Dermatology, Harvard Medical School. He commented: “The compelling science behind Pelage’s approach signals an exciting opportunity to potentially reverse the effects of alopecia, an issue I see daily in my clinical practice. Hair loss impacts an incredibly diverse patient population, which should be reflected in early clinical trials.”
Diana Spencer, Senior Digital Content Editor, DDW
